Indegene Ltd (INDGN) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported strong growth, with revenue increasing by 30.8% YoY and 17.1% QoQ, driven by both organic performance and the acquisition of Biopharm.
- Organic growth remained robust at 18.3% YoY and 5.9% QoQ, indicating healthy underlying business momentum.
- Significant new business was secured, highlighted by seven large deals each exceeding $1 million in annual contract value (ACV), including a notable $20 million total contract value (TCV) deal to be an end-to-end commercialization partner for a mid-size biotech company.
- The company demonstrated successful client relationship expansion, with the number of $1 million+ customers growing by 12 to a total of 52, and active customers increasing by 10 to 86.
- Strategic integration of GenAI-based platforms is a core focus, enabling productivity gains and volume expansion by allowing clients to undertake more complex work, positioning Indegene as a key partner in the industry's digital transformation.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.